Baird analyst Catherine Ramsey Schulte maintains $Castle Biosciences (CSTL.US)$ with a buy rating, and adjusts the target price from $37 to $39.
According to TipRanks data, the analyst has a success rate of 54.5% and a total average return of 12.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Castle Biosciences (CSTL.US)$'s main analysts recently are as follows:
Castle Biosciences reported a robust third quarter, with revenues meeting expectations and showing promising operational expenditure leverage. The company experienced overall volume growth, although dermatology volumes fell short of estimates because of seasonal factors. Meanwhile, the TissueCypher product continued to display significant momentum.
The company's continuous expansion of volumes for its variety of tests, including growth seen in IDgenetix and TissueCypher, has been a contributing factor to the robust quarterly results and the elevated revenue forecasts.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
